Description
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
This trial is available at multiple Sutter Locations. Please contact one of the following about Study NRG GY018
San
Francisco: ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky
pozniat@sutterhealth.org
East Bay: James Nasman NasmanJ@sutterhealth.org and
Vivian Leong, RN Leongv@sutterhealth.org
Sacramento: Isabel Rodrigues-Fong Rodrigi@sutterhealth.org
and Kirsten Babski babskik@sutterhealth.org
Modesto: Delia Massone MassonD@sutterhealth.org
and Adrienne Palos PalosA@sutterhealth.org
Solano-Vallejo Cancer Center: Stephanie
Gonzales gonzals@sutterhealth.org
Principal Investigator
Recruitment Status
Active, Not Recruiting
Start Date
February 03, 2020